Efficacy of intravenous immunoglobulin monotherapy in patients with cutaneous lupus erythematosus: results of proof-of-concept study

Christa Ky,1 Brian Swasdibutra,1 Shaadi Khademi,1 Sheetal Desai,2 Vivian Laquer,1 Sergei A. Grando1,3,4
1Department of Dermatology, 2Division of Rheumatology, Department of Medicine, 3Department of Biological Chemistry, 4Institute for immunology, University of California, Irvine, CA, USA

Abstract

Cutaneous lupus erythematosus (CLE) is a chronic inflammatory autoimmune skin disease. Evidence-based therapy for CLE is lacking in the most part. Intravenous immunoglobulin (IVIg) is being increasingly utilized as off-label therapy for a variety of autoimmune and inflammatory conditions, especially in dermatology. The usefulness of IVIg in CLE is not well established. The goal of the present study was to obtain the proof-of-concept evidence that IVIg can control acute CLE and thus replace current systemic immunosuppressive therapy that causes severe side effects and adverse reactions. Sixteen patients who tried and failed various systemic treatments for CLE were screened and consented to use IVIg as a monotherapy. The IVIg was administered at 500 mg/kg/day on 4 consecutive days up to a total of 2 g/kg/month for 3 months, and the subjects were monitored for additional 6 months off any drug for a possible relapse. The cumulative results revealed an overall improvement, as evinced by a decrease of both objective and subjective measures of disease activity. The most sensitive and specific objective and subjective instruments for assessment of the therapeutic effect of IVIg were CLASI-A (Cutaneous Lupus Erythematosus Disease Area and Severity Index) measuring disease activity and Skindex-29 scores, respectively. The CLASI-A score dropped down from the initial value taken as 100%, and remained in the range of approximately 70% until the last visit. Three patients (18.8%) had a temporary healing that may cause permanent scarring. Discoid lupus erythematosus, subacute cutaneous lupus erythematosus, lupus panniculitis and lupus erythematosus tumidus all fall into the category of CLE. Face and scalp are most commonly affected by scarring in the discoid form of CLE. The etiology and pathogenesis of CLE are multifactorial with genetic and environmental factors playing a role. Photosensitivity, polymorphisms of the major histocompatibility complex leading to increased immune response to self-antigens, deficiencies of complement components, gender, and autoantibodies are all thought to play a role. Anti-Ro, anti-La, anti-dsDNA and antinucleosome antibodies are thought to play a role in skin disease by increased skin cell apoptosis. Dysregulation of T cells may also play a role in the pathogenesis of CLE.1,2

Evidence-based therapy for CLE is lacking. Administration of systemic immunosuppressive and anti-inflammatory agents, such as corticosteroids, hydroxychloroquine, meperidine, methotrexate, mycophenolate mofetil, cyclophosphamide and azathioprine, in many cases, leads to remission. Nevertheless, many patients suffer from resistant cutaneous lesions despite therapy. Alternative systemic (dapsone, thalidomide, retinoids, cyclosporine) and topical agents (thalidomide, intraleional steroids, retinoids, tacrolimus ointment) as well as laser therapy, phototherappy, photopheresis, and crotophoresis are used for resistant cutaneous lesions, but a positive outcome is not guaranteed.3-5

Intravenous immunoglobulin (IVIg) is a fractioned blood product consisting of pooled, polyvalent, IgG antibody extracted from the plasma of over 10,000 blood donors per batch. Historically, it was used to treat primary and secondary immune deficiencies, however, its use has expanded tremendously over the past several decades. Today, it is being increasingly utilized as off-label therapy for a variety of autoimmune and inflammatory conditions, especially in dermatology. IVIg exhibits several effects with the most well described being: i) complement blockade and degradation; ii) neonatal Fc receptor saturation; iii) induction of immunomodulatory Fc receptors; iv) inhibition of B cells; and v) altering T cell function, cytokine production and migration.6 The increasing use of IVIg has been associated with further understanding of its mechanisms of action, clinical manipulation and associated side effects, as well as the introduction of improved or new types of IVIg products. Ongoing research continues to elaborate and identify novel mechanisms. One area in which IVIg is continuing to make dramatic improvements is the ability to treat derangements of immunity in immune-mediated diseases.7 Although the usefulness of IVIg in CLE is not well established, IVIg has been used to successfully treat CLE, either as monotherapy or in conjunction with an immunosuppressant.8,11-13

The first report in 1997 described 7 female patients treated with IVlg at a dosage of 300 mg/kg per day for 5 consecutive days each month for a 12-month period.14 Although some clinical symptoms, such as asthenia, arthromyalgia, and fever, disappeared in some patients and immunologic parameters improved, IVlg was not able to improve the cutaneous manifestations. Moreover, skin lesions of CLE worsened. The vast majority of subsequent reports, however, demonstrated an overall good efficacy of IVlg in resistant cases.8,10-13,15 For instance, in the responding patients, the duration of the remission ranged from 2 months to more than 1 year, suggesting that repeated pulses of IVlg could be used as maintenance therapy. For example, IVlg showed beneficial effects in a 2-day course (1 g/kg per day) every 4 weeks in 5 patients with refractory extensive long-lasting discoid CLE.

Introduction

Cutaneous lupus erythematosus (CLE) is a chronic inflammatory autoimmune skin disease that may cause permanent scarring. Photosensitivity, polymorphisms of the major histocompatibility complex leading to increased immune response to self-antigens, deficiencies of complement components, gender, and autoantibodies are all thought to play a role. Anti-Ro, anti-La, anti-dsDNA and anti-nucleosome antibodies are thought to play a role in skin disease by increased skin cell apoptosis. Dysregulation of T cells may also play a role in the pathogenesis of CLE.1,2

Evidence-based therapy for CLE is lacking. Administration of systemic immunosuppressive and anti-inflammatory agents, such as corticosteroids, hydroxychloroquine, meperidine, methotrexate, mycophenolate mofetil, cyclophosphamide and azathioprine, in many cases, leads to remission. Nevertheless, many patients suffer from resistant cutaneous lesions despite therapy. Alternative systemic (dapsone, thalidomide, retinoids, cyclosporine) and topical agents (thalidomide, intraleional steroids, retinoids, tacrolimus ointment) as well as laser therapy, phototherappy, photopheresis, and crotophoresis are used for resistant cutaneous lesions, but a positive outcome is not guaranteed.3-5

Intravenous immunoglobulin (IVIg) is a fractioned blood product consisting of pooled, polyvalent, IgG antibody extracted from the plasma of over 10,000 blood donors per batch. Historically, it was used to treat primary and secondary immune deficiencies, however, its use has expanded tremendously over the past several decades. Today, it is being increasingly utilized as off-label therapy for a variety of autoimmune and inflammatory conditions, especially in dermatology. IVIg exhibits several effects with the most well described being: i) complement blockade and degradation; ii) neonatal Fc receptor saturation; iii) induction of immunomodulatory Fc receptors; iv) inhibition of B cells; and v) altering T cell function, cytokine production and migration.6 The increasing use of IVIg has been associated with further understanding of its mechanisms of action, clinical manipulation and associated side effects, as well as the introduction of improved or new types of IVIg products. Ongoing research continues to elaborate and identify novel mechanisms. One area in which IVIg is continuing to make dramatic improvements is the ability to treat derangements of immunity in immune-mediated diseases.7 Although the usefulness of IVIg in CLE is not well established, IVIg has been used to successfully treat CLE, either as monotherapy or in conjunction with an immunosuppressant.8,11-13

The first report in 1997 described 7 female patients treated with IVlg at a dosage of 300 mg/kg per day for 5 consecutive days each month for a 12-month period.14 Although some clinical symptoms, such as asthenia, arthromyalgia, and fever, disappeared in some patients and immunologic parameters improved, IVlg was not able to improve the cutaneous manifestations. Moreover, skin lesions of CLE worsened. The vast majority of subsequent reports, however, demonstrated an overall good efficacy of IVlg in resistant cases.8,10-13,15 For instance, in the responding patients, the duration of the remission ranged from 2 months to more than 1 year, suggesting that repeated pulses of IVlg could be used as maintenance therapy. For example, IVlg showed beneficial effects in a 2-day course (1 g/kg per day) every 4 weeks in 5 patients with refractory extensive long-lasting discoid CLE.
with major face involvement. Relapses occurred 2 to 10 months after IVIg withdrawal and skin lesions were controlled again with IVIg in one patient with discoid CLE. In another case report, one patient with resistant CLE was treated with IVIg (2 g/kg per month) and showed dramatic improvement within 3 months and almost complete resolution after 6 months. Three patients with CLE unresponsive to previous therapy were treated with IVIg, which achieved good response of their skin lesions. Twelve patients with histologically confirmed CLE were given IVIg with starting doses of 1 g/kg per day on 2 consecutive days, followed by 400 mg/kg per month for 6 months or until disease resolution. Five patients had complete or near complete clearing of their skin disease (>75% clearing), two had partial improvement (~50% clearing), and three had limited response (<50% clearing). Others reported a female patient with highly recalcitrant CLE who responded very well to treatment with IVIg (1 g/kg per day on 3 consecutive days per month). Amelioration was observed after the first cycle followed by an almost complete clearing. More recently, a case of CLE successfully treated with IVIg was reported after other therapy modalities failed. Thus, the available data strongly suggest that patients with CLE may benefit from a therapy with IVIg. However, a recommended or defined protocol for patients with CLE does not exist.

The goal of the present study was to obtain the proof-of-concept evidence that IVIg can control acute CLE and thus replace current systemic immunosuppressive therapy that causes severe side effects and adverse reactions. From the review of literature, we postulated that: i) the beneficial effects of IVIg for patients with CLE should be prompt, with marked improvement within a few weeks; and ii) clinical improvement should last several weeks after the last infusion.

Materials and Methods

For this small scale exploratory consecutive case-series type of study, subjects were recruited from an outpatient CLE patient population treated at the University of California, Irvine. Sixteen patients who received a standard therapy without a therapeutic response for a minimum of one month were screened and consented to use IVIg as a monotherapy. Our patients have tried and failed various systemic treatments for CLE, such as prednisone, plaquenil and dapsone. Topical treatment with clobetasol or tacrolimus, which was not effective either, was stopped at the beginning of IVIg therapy.

Inclusion criteria: males and females ≥18 years of age; active CLE (any subtype) established by standard clinical and histo- and immunopathological criteria; understands and follows directions.

Exclusion criteria: subjects <18 years of age; cannot understand or follow directions; a pregnant, planning to get pregnant or breast feeding female; a female of child-bearing potential and unwilling to use a form of highly effective birth control; has one or more of the following problems: IgA deficiency, HIV infection, organ transplant, severe anemia, jaundice, major organ failure, creatinine >1.5 mg/dL or hemoglobin <11.0 g/dL.

All enrolled subjects received IVIg treatment following the protocol that proved to be efficacious in the treatment of patients with autoimmune blistering diseases as well as previously treated patients with CLE. The IVIg (GAMUNEX-C, Grifols, Los Angeles, CA, USA) was administered at 500 mg/kg/day on 4 consecutive days up to a total of 2 g/kg/month for 3 months in the Institute for Clinical and Translational Science at University of California, Irvine. After 3 months of treatment, IVIg was discontinued and the subjects were monitored for additional 6 months off any drug for a possible relapse.

Upon entry into the study, the study subject’s severity of CLE was evaluated using the following instruments: Physician’s Subjective Assessment of Severity (PSAS; mild, moderate or severe), Physician’s Subjective Assessment of Improvement (PSAI; improved, unchanged or worse), and Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) measuring both the activity of the disease (CLASI-A) and the damage done by the disease (CLASI-D). The higher scores indicated more severe skin disease.16 The subjects also evaluated their skin-specific quality of life with the Skindex-29 — the questionnaire consisting of 29 items used to calculate three subscales: symptoms (pain, itch, burning, sensitivity), emotions (depression, anxiety, embarrassment, anger) and functioning (sleep, relationships with others).16 All assessments were repeated at all study visits.

Results

We have enrolled and treated 15 female and 1 male CLE patients aged 19-70 years with 3 monthly cycles of IVIg monotherapy. The cumulative results of assessment of clinical efficacy of IVIg in the enrolled patients revealed an overall improvement, as evidenced by a decrease of both objective and subjective measures of disease activity. The most sensitive and specific objective and subjective instruments for assessment of the therapeutic effect of IVIg were CLASI-A and Skindex-29 scores, respectively (Table 1). The individual variations of CLASI-A and Skindex-29 scores are shown in Figure 1. All other measured parameters, CLASI-D, PSAS and PSAI, did not

Table 1. The clinical response scores (%) in enrolled cutaneous lupus erythematosus patients treated by intravenous immunoglobulin monotherapy.

<table>
<thead>
<tr>
<th>Clinical evaluation test</th>
<th>Initial visit (n=16)</th>
<th>1st visit (n=14)</th>
<th>2nd visit (n=12)</th>
<th>3rd visit (n=9)</th>
<th>4th visit (n=6)</th>
<th>5th visit (n=6)</th>
<th>6th visit (n=6)</th>
<th>7th visit (n=5)</th>
<th>8th visit (n=6)</th>
<th>9th visit (n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLASI-A</td>
<td>100</td>
<td>94</td>
<td>84</td>
<td>94</td>
<td>86</td>
<td>85</td>
<td>72</td>
<td>68</td>
<td>81</td>
<td>71</td>
</tr>
<tr>
<td>CLASI-D</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>PSAS</td>
<td>100</td>
<td>98</td>
<td>100</td>
<td>97</td>
<td>92</td>
<td>92</td>
<td>92</td>
<td>92</td>
<td>90</td>
<td>92</td>
</tr>
<tr>
<td>PSAI</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>136</td>
<td>104</td>
<td>105</td>
<td>117</td>
<td>133</td>
<td>15</td>
<td>100</td>
</tr>
<tr>
<td>Skindex-29</td>
<td>100</td>
<td>97</td>
<td>94</td>
<td>92</td>
<td>90</td>
<td>81</td>
<td>79</td>
<td>83</td>
<td>99</td>
<td>92</td>
</tr>
</tbody>
</table>

CLASI, cutaneous lupus erythematosus disease area and severity index; PSAI, physician’s subjective assessment of severity; PSAS, physician’s subjective assessment of improvement. Results are expressed as a relative mean value determined for the entire group of cutaneous lupus erythematosus on a particular visit number, compared to the pre-treatment value for the corresponding test, taken as 100%. Number of patients per each particular time-point (i.e., visit number), for whom the mean value was calculated.
correlate with clinical improvement. As seen in Table 1, on the 7th visit after starting IVlg treatment, the CLASI-A score dropped down to 68% from the initial value taken as 100%, and remained in the range of approximately 70% until the last visit. Skindex-29 was found to be an informative subjective measure, showing a drop to 79% from the initial 100% on the 6th visit (Table 1). After that, Skindex-29 has increased again.

First dose response was indicated by a steady decrease in CLASI-A between the baseline and the 1st month after starting IVlg treatment. Five patients had a decrease in CLASI-A that persisted for the rest of the study. Three patients (18.8%) had a temporary flare of CLE symptoms categorized as a relapse of the disease. All patients recovered within a month from the relapse. In one patient, the CLASI-A score increased from 7 to 10 but then dropped to 8. In a second patient, the CLASI-A score increased from 2 to 5 and then decreased back to 2. In a third patient, the CLASI-A score increased from 14 to 17 but then dropped to 9. No serious side effects and adverse reactions occurred. Two patients developed mild anemia, 1 mild neutropenia, 5 headache, 1 back aches, 1 high blood pressure, 2 fever, 1 gastro-intestinal upset, 2 nausea/vomiting, and 1 herpes-associated erythema multiforme. These are commonly seen in patients with various medical conditions receiving IVlg therapy.

Discussion

The results of this proof-of-concept study of clinical efficacy of a short-term IVlg monotherapy in CLE produced very promising results, as evidenced by: i) rapid and persistent decreased in disease activity measured by CLASI-A scores; ii) steady improvement of patients’ quality of life assessed by Skindex-29; iii) low relapse rate; and iv) mild nature and short duration of relapses.

Since healing was maintained for months after IVlg treatment, it is possible that the IVlg-triggered molecular events mediating the therapeutic action of IVlg that continued to unfold after the end of therapy. The results of this study thus provide the basis for hypotheses for the future multicenter randomized controlled studies to identify which CLE subsets will benefit the most and which protocol will provide the optimal clinical outcome.

The obtained results indicated that a minimum of 3 treatment cycles with IVlg at 2 g/kg/month were needed to achieve clinical response. However, the fact that both CLASI-A and Skindex-29 scores showed a tendency to increase after reaching the minimal values strongly suggests that more cycles of IVlg monotherapy are required to achieve a stable clinical remission off any drugs. This would be in keeping with duration of IVlg therapy required to achieve stable remission in patients with autoimmune blistering dermatoses. For examples, an average number of IVlg cycles (i.e., months) of treatment of patients with pemphigus and pemphigoid is equal to 38.6.17 Thus, while the use of IVlg allows achievement of rapid remission of CLE, the maintenance therapy with repeated monthly pulses of IVlg for an extended period of time should maintain the disease in remission. Future clinical trials should determine the optimal number of cycles of treatment for patients with distinct CLE forms by IVlg monotherapy.

In this study, CLASI-A was the most sensitive measure of treatment efficacy. The obtained results are comparable to those reported by the others who tested the efficacy of CLE treatment by pulsed dye laser treatment or Vitamin D.18,19 Overall, CLASI score measurement shows good content validity, addresses the most relevant aspects of all subsets of CLE, including individual lesions localized and generalized CLE, and also has good inter-rater
and intra-rater reliability when used by either dermatologists or rheumatologists. In marked contrast, CLASI-D remained unchanged for all but 2 patients, as could be expected for such a short-term study, given the irreversible nature of skin damage in CLE, e.g., scars. The CLASI-D result is comparable to other CLE studies that have been shown to treat CLE.

The relapses in the three of our patients, defined as an increase in CLASI-A score, were mild, because within one month, their CLASI-A became comparable to or even lower than that prior to the relapse. In our patients, the relapse rate was much lower, compared to that reported in the literature for CLE patients. For comparison, in other clinical trials the relapse rate was reported at the range of 70-80%.

Conclusions

We can conclude that: i) IVlg monotherapy clearly alleviated symptoms in patients with different clinical forms of CLE resistant to standard treatments, which should justify a multi-center clinical trial on a larger number of patients to ultimately establish the efficacy of IVlg in each clinical form of CLE; ii) three monthly cycles of 2 g/kg/month of IVlg were sufficient to achieve a stable remission, but the symptoms may return, indicating the need for a more extended duration IVlg monotherapy of CLE, by analogy with other mucocutaneous autoimmune diseases; iii) CLASI-A and Skindex-29 appeared to be the most sensitive objective and subjective, respectively, instruments for analysis of clinical efficacy of IVlg in patients with CLE, and, therefore, should be employed for assessment of treatment efficacy in future clinical trials of IVlg in CLE; iv) treatment with IVlg dramatically decreases the frequency and severity of relapses, compared to some previously tested therapies CLE patients.

References